Schedule a Meeting
Download Brochure
Table of Content
October 2024
.webp)
Principal Consultant
Reviewed By
The global antimicrobial resistance surveillance market size is calculated at USD 6.28 billion in 2024, will grow to USD 6.63 billion in 2025, and is projected to reach around USD 10.84 billion by 2034, rising at a 5.64% CAGR for the forecasted period 2024 to 2034.
Antimicrobial resistance surveillance (AMR) refers to the ongoing process of monitoring and analyzing data on how microorganisms, such as bacteria and viruses, develop resistance to antimicrobial treatments. This system helps detect trends, identify outbreaks of resistant infections, and guide effective responses in healthcare and public health settings. AMR surveillance is essential for informing treatment guidelines, shaping policy, and supporting global efforts to control the spread of resistant pathogens. The Centers for Disease Control reports over 2.8 million antimicrobial-resistant infections yearly in the U.S., while the WHO considers antimicrobial resistance a major global health threat. The antimicrobial resistance surveillance market is growing due to the growing threat of drug-resistant infections. These infections are harder to treat, increasing the need for an effective monitoring system.
Artificial intelligence (AI) is revolutionizing the antimicrobial resistance (AMR) surveillance market by enabling faster, more accurate detection of resistant pathogens. It can quickly analyze patient data and lab results to identify resistance patterns, supporting timely and targeted treatment decisions. AI also helps predict emerging resistance trends, aiding in outbreak prevention. By streamlining data collection and reporting, it enhances surveillance efficiency across healthcare systems. Additionally, AI supports drug development by identifying potential antibiotic candidates and simulating resistance scenarios. When integrated with diagnostic tools, AI delivers real-time insights, improving infection control and personalized treatment strategies in clinical settings.
A Growing Number of Drug-resistant Infection
A growing number of drug-resistant infections, such as those caused by MRSA, VRE, and MDR-TB, pose serious treatment challenges. Technological advancements in diagnostics have also improved the speed and accuracy of detecting resistant pathogens, further encouraging the adoption of surveillance systems. Additionally, strong support from government and global health organizations through policies and funding is boosting the development of AMR monitoring infrastructure. Increased awareness among healthcare professionals and the need for infection control in hospitals are also fueling the antimicrobial resistance surveillance market growth.
High Cost of Antimicrobial Resistance Diagnostic Systems
Many healthcare facilities, especially in low- and middle-income countries, cannot afford to implement or maintain these advanced technologies. These systems often require equipment, skilled personnel, and ongoing maintenance, which limits widespread adoption. As a result, it hinders the ability to effectively monitor and respond to AMR threats on a larger scale. NorthShore University Health System states that running 29,200 tests yearly with automated systems costs about USD 165,856 for regents, while the disk diffusion method costs only USD 43,508. This means automated systems cost around USD 90,668 more per year than semi-automated methods, highlighting the higher operational costs associated with advanced diagnostic technologies.
Growing Adoption of Genomic and Molecular Surveillance Technologies
These advanced techniques allow for faster, more accurate detections of resistance patterns and genes, providing critical insights into the spread of antimicrobial resistance. As healthcare systems embrace precision medicine and focus on more targeted treatments, the demand for real-time, detailed data will continue to grow. This presents significant opportunities for expanding surveillance capabilities, particularly in hospitals, research institutions, and public health organizations looking to combat drug-resistant infections more effectively and improve patient outcomes.
By Solution, the diagnostics kits segment held a dominant presence in the antimicrobial resistance surveillance market in 2024. Diagnostics kits provide quick, accurate, and cost-effective solutions for identifying antimicrobial resistance, enabling healthcare providers to make timely decisions regarding treatment. With the increasing need for rapid testing to manage drug-resistant infections, these kits offer significant advantages in clinical settings. Rapid detection has been key in guiding personalized treatment for patients with antimicrobial-resistant infections, helping target the right therapy for better outcomes. Their ease of use, reliability, and essential role in strengthening global AMR monitoring and control efforts have significantly contributed to their widespread adoption.
By Solution, the surveillance software segment is anticipated to grow at the fastest rate in the antimicrobial resistance surveillance market during the studied years. The a growing need for advanced data analytics, real-time monitoring, and efficient management of large volumes of health data. These solutions allow seamless integration across hospitals, laboratories, and public health systems, enabling quick detection of resistance patterns and supporting national and global antimicrobial resistance (AMR) surveillance efforts, making them increasingly vital.
By application, the clinical diagnostics segment was dominant in the market in 2024. The growing burden of drug-resistant infections and the urgent need for accurate and timely detection in healthcare settings. Clinical diagnostics are crucial in identifying resistant pathogens directly from patient samples, enabling physicians to make informed treatment decisions and reduce the misuse of antibiotics. Their integration into route hospital workflows and their role in tracking resistance trends made them vital tools for real-time surveillance, infection control, and overall management of AMR, contributing significantly to their antimicrobial resistance surveillance market dominance.
By application, the public health surveillance segment is expected to grow at the fastest rate in the coming years. Government and International organizations are investing heavily in strengthening surveillance systems to track resistant pathogens more effectively. The integration of advanced technologies such as artificial intelligence and machine learning is further enhancing this system by enabling real-time data analysis, early detection, and improved decision-making. These efforts are crucial for managing AMR, ensuring better infection control, and implementing targeted interventions, making public health surveillance fight against antimicrobial resistance.
By end user, the hospitals & clinics segment held the highest share of the market in 2024. Due to their central role in diagnostics, treating, and preventing drug-resistant infections. These healthcare settings manage a high number of hospital-acquired infections, where resistance is often more prevalent. Hospitals and clinics are crucial for monitoring resistance patterns and ensuring that appropriate infection control protocols are followed. Additionally, they are required to comply with various healthcare regulations that mandate AMR surveillance, making them key contributors to global resistance tracking efforts. Hospitals & clinics' involvement in adhering to public health regulations, monitoring antibiotic usage, and adopting advanced diagnostics technologies further drives their dominant position in the antimicrobial resistance surveillance market.
By end user, the research & academic institutes segment is estimated to grow at the fastest rate during the predicted timeframe. These institutions are involved in extensive research, developing new diagnostics methods, therapies, and surveillance strategies to combat AMR. Their work contributes to global health policies and provides valuable data for public health initiatives. Additionally, increased funding from the government and organizations for AMR-related research is further fueling growth, as these institutions lead efforts in finding innovative solutions to the growing threat of antimicrobial resistance.
North America dominated the global antimicrobial resistance surveillance market in 2024 due to advanced healthcare infrastructure, high prevalence of resistant infection, and strong government support. The region faces millions of antimicrobial resistance cases annually, driving the urgent need for effective surveillance systems. Additionally, the presence of leading pharmaceutical and biotech companies, along with strict regulatory frameworks enforced by agencies like the CDC, has enhanced data collection, diagnostic, and response strategies solidifying North America.
The U.S. market is growing rapidly due to the rising number of drug-resistant infections and strong government initiatives like the PASTEUR Act, which supports antibiotic development. Advances in diagnostics technologies, such as rapid molecular testing and next-generation sequencing, are improving detection and response times. The CDC supports this growth through major investment in AMR research and surveillance. Integration of artificial intelligence, rapid diagnostic tools, and antimicrobial stewardship programs enhanced early detection and monitoring.
According to the CDC 2023 data, the U.S. sees over 2.8 million antimicrobial-resistant infections each year. To address this, the government invested $197 million in 2023. This funding is aimed at improving prevention, diagnostics, and surveillance of antibiotic-resistant infections through CDC-led initiatives.
Canada’s market is growing due to rising drug-resistant infections, government funding, and advanced diagnostics technologies. The Public Health Agency of Canada supports antimicrobial stewardship and national monitoring programs to improve antibiotic use. Innovations like rapid testing and tools enhance detection. Canada also uses an Ine Health approach, integrating human, animal, and environment data through programs like CIPARS. These combined efforts strengthen surveillance and drive the expansion of the AMR market in Canada.
Asia-Pacific is anticipated to grow at the highest CAGR in the antimicrobial resistance surveillance market during the forecast period. Rapid urbanization and population growth in countries like China and India are leading to increased antibiotic consumption, both in healthcare and agriculture, thereby accelerating the development of resistant pathogens. Additionally, the region's expanding healthcare infrastructure, rising awareness of AMR, and growing investment in diagnostic technologies are further driving market growth.
For instance,
China’s market is expanding due to the increasing prevalence of drug-resistant infections and significant advancements in diagnostic technologies. The Chinese government and One Health National Action Plan to Tackle AMR comprehensively. Innovations such as molecular diagnostics, rapid testing, and whole-genome sequencing are enhancing the efficacy of AMR detection. Additionally, the government is promoting research and funding to combat AMR, strengthening the infrastructure and capacity for effective monitoring and response.
India’s market is expanding due to the rising incidence of drug-resistant infections such as MRSA, VRE, and multidrug-resistant tuberculosis. This growing health threat has driven the adoption of advanced diagnostic technologies, including rapid susceptibility testing and molecular diagnostics, to improve detection and treatment. Additionally, increasing healthcare investment and wider implementation of antimicrobial programs are strengthening the country’s surveillance capacity, further driving market growth.
Europe is expected to see significant growth in the antimicrobial resistance surveillance market during the forecast period due to a growing number of drug-resistant infections and strong government support. According to the ECDC 2023 report, over 670,000 antibiotic-resistant infections occur annually in the EU, largely caused by the overuse and misuse of antibiotics. Supporting this, OECD 2023 data reveals that the EU spends approximately 1.1 billion each year to tackle antimicrobial resistance, highlighting the region's significant financial and healthcare burden related to AMR. Governments across the region are investing in national surveillance networks and antimicrobial stewardship programs to improve antibiotic use and track resistance patterns. Additionally, technological advancements in rapid diagnostics and AI tools are further enhancing detection, contributing to market expansion.
Germany’s market is expanding due to the rising incidence of drug-resistant infections, including MRSA and CRE, which has increased the demand for advanced surveillance systems. The country is benefiting from significant investment in diagnostic technologies, such as molecular techniques and rapid antimicrobial susceptibility testing, improving detection accuracy. The integration of real-time surveillance platforms, CRISPR-Cas systems, and AI tools has also enhanced AMR monitoring, contributing to market growth.
France's market is growing due to strong infrastructure, cross-sector collaboration, and investment in innovation. The country has strengthened its surveillance by supporting integrated data-sharing systems among hospitals, veterinary services, and environmental agencies, which enhances its ability to detect resistance trends early. Additionally, France continues to invest in regional laboratories and expand electronic health records to streamline diagnostic reporting. Support from academic institutes and collaboration with biotech firms are also fostering research-driven advancements, further boosting the country’s AMR surveillance capabilities.
In June 2024, the FAO launched InFARM, a global information system to strengthen national surveillance of antimicrobial resistance (AMR) in animals and food. The initiative supports the collection of reliable, timely AMR data at national, regional, and global levels. As part of the launch, FAO has opened its first annual data call for 2024, inviting Member States to participate. Alejandro Dorado García, FAO’s AMR surveillance coordinator, highlighted that upcoming training in Colombia will demonstrate how InFARM helps implement Codex Guidelines, marking an important step in the global fight against AMR.
By Solutiob
By Application
By End User
By Region
October 2024